ClearPoint Neuro director settles 12,417 RSUs

ClearPoint Neuro director Timothy T. Richards exercised 12,417 restricted stock units into 12,417 shares of common stock.

Rhea-AI Filing Summary

ClearPoint Neuro director Timothy T. Richards exercised 12,417 restricted stock units into 12,417 shares of common stock. The RSUs were granted on May 22, 2025 and vested on their scheduled vesting date, converting into common shares at no cash exercise price.

Following this settlement of equity compensation, Richards directly owns 92,613 shares of ClearPoint Neuro common stock. The filing does not show any open-market purchases or sales, only the vesting and share issuance related to previously granted RSUs.

Insider Trade Summary

12,417 shares exercised/converted

Exercise 2 txns

Insider Richards Timothy T.

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	12,417	$0.00	$0.00
Exercise	Common Stock	12,417	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 0 contracts (Direct); Common Stock — 92,613 shares (Direct)

Footnotes (1)

1. F1. Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 22, 2025, the reporting person was granted 12,417 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

Key Figures

RSUs settled: 12,417 units Common shares received: 12,417 shares Shares held after transaction: 92,613 shares +2 more

5 metrics

RSUs settled 12,417 units Restricted stock units converting into common stock

Common shares received 12,417 shares Shares issued upon RSU vesting

Shares held after transaction 92,613 shares Direct common stock ownership post-settlement

Exercise price $0.00 per share RSU conversion price to common stock

Grant size 12,417 RSUs RSUs granted on May 22, 2025

Key Terms

Restricted Stock Units, derivative security, scheduled vesting date

3 terms

Restricted Stock Units financial

"Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. common stock."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

derivative security financial

"Transaction code M is described as an Exercise or conversion of derivative security."

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

scheduled vesting date financial

"This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ClearPoint Neuro (CLPT) report for Timothy T. Richards?

ClearPoint Neuro reported that director Timothy T. Richards settled 12,417 restricted stock units into 12,417 shares of common stock. This reflects the scheduled vesting of an equity grant, rather than an open-market purchase or sale of CLPT shares.

How many ClearPoint Neuro shares does Timothy T. Richards hold after this Form 4?

After the RSU settlement, Timothy T. Richards directly holds 92,613 shares of ClearPoint Neuro common stock. This total reflects his position immediately following the conversion of 12,417 restricted stock units into an equal number of CLPT common shares.

Were the ClearPoint Neuro (CLPT) shares in this Form 4 bought or sold on the market?

The shares were not bought or sold on the open market. The Form 4 shows 12,417 restricted stock units converting into 12,417 common shares at a zero exercise price as part of scheduled vesting, with no open-market purchase or sale activity disclosed.

What are restricted stock units (RSUs) in the ClearPoint Neuro filing?

In this filing, each restricted stock unit represents a contingent right to receive one ClearPoint Neuro common share. The 12,417 RSUs granted on May 22, 2025 vested and were settled in an equal number of shares on their scheduled vesting date.

When were the ClearPoint Neuro RSUs for Timothy T. Richards originally granted and how did they vest?

The 12,417 restricted stock units were granted on May 22, 2025. They vested on the earlier of the first anniversary of the grant date or the day immediately preceding ClearPoint Neuro’s 2026 annual meeting, then settled into 12,417 common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/21/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Richards Timothy T.

(Last) (First) (Middle)

C/O CLEARPOINT NEURO, INC.

120 S. SIERRA AVE., SUITE 100

(Street)

SOLANA BEACH CALIFORNIA 92075

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ClearPoint Neuro, Inc. [ CLPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/19/2026		M		12,417	A	(1)	92,613	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	05/19/2026		M			12,417	(1)	(1)	Common Stock	12,417	(1)	0	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 22, 2025, the reporting person was granted 12,417 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

	/s/ Danilo D'Alessandro, by Power of Attorney for Timothy T. Richards	05/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)